Abstract
Background
This study was designed to test whether circulating levels of myocardium-specific
proteins serve as useful markers for the prognosis of patients with congestive heart
failure.
Methods and Results
Seventy-eight patients with congestive heart failure from dilated cardiomyopathy but
in a stable condition were enrolled, and their blood was sampled for measurements
of myosin light chain-I (MLC-I), troponin T (TnT), heart fatty-acid-binding protein
(H-FABP), and creatine kinase isoenzyme MB (CK-MB). The patients were then followed
up for 951 ± 68 days, with the endpoint being acute deterioration. A univariate analysis
revealed that MLC-I, TnT, H-FABP, and CK-MB were significant predictors for acute
deterioration of heart failure. Application of the Kaplan-Meier method using cutoff
values determined by analysis of receiver operating characteristics curves demonstrated
that the incidence of acute deterioration was significantly higher in patients with
higher values of MLC-I (61.9%), TnT (52.4%), H-FABP (50.0%), or CK-MB (38.6%) than
in those with lower values of these markers (15.8%, 20.4%, 13.6%, and 16.1%, respectively).
Conclusions
Increased circulating levels of the specific myocardial proteins are related to a
higher probability of future acute deterioration of congestive heart failure in patients
in a stable condition associated with dilated cardiomyopathy.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Cardiac FailureAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Successes and failures of current treatment of heart failure.Lancet. 1998; 352: SI19-SI28
- Survival after the onset of congestive heart failure in Framingham Heart Study subjects.Circulation. 1993; 88: 107-115
- Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.Circulation. 1993; 87: VI40-VI48
- Hormones and hemodynamics in heart failure.N Engl J Med. 1999; 341: 577-585
- Neurohumoral blockade in CHF management.J Renin Angiotensin Aldosterone Syst. 2000; 1: 24-30
- Neurohumoral control mechanisms in congestive heart failure.Am Heart J. 1981; 102: 509-514
- Contributions of neuroendocrine and local autocrine-paracrine mechanisms to the pathophysiology and pharmacology of congestive heart failure.Am J Cardiol. 1988; 62: 76E-81E
- Hormones in heart failure—regulation and counterregulation.Eur Heart J. 1991; 12: 190-192
- Molecular and cellular mechanisms of myocardial failure.Am J Cardiol. 1997; 80: 15L-25L
- Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition.Circulation. 1995; 91: 2504-2507
- Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure.Am J Cardiol. 2002; 89: 691-695
- Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan.Am J Cardiol. 2002; 90: 969-973
- Serial measure of cardiac troponin T levels for prediction of clinical events in decompensated heart failure.J Card Fail. 2004; 10: 43-48
- Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure.Am J Med. 2002; 113: 717-722
- Circulating levels of cardiac proteins indicate severity of congestive heart failure.Heart. 2003; 89: 1303-1307
- Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide.J Clin Invest. 1991; 87: 1402-1412
- Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population.Heart. 2001; 86: 21-26
- Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1.Eur Heart J. 1999; 20: 1799-1807
- Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure.J Am Coll Cardiol. 2001; 38: 1934-1941
- Natriuretic peptide system in human heart failure.Circulation. 1993; 88: 1004-1009
- Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy.Circulation. 1991; 83: 504-514
- Structural basis of end-stage failure in ischemic cardiomyopathy in humans.Circulation. 1994; 89: 151-163
- Cellular mechanisms of contractile dysfunction in human heart failure.Eur Heart J. 1996; 17: 189-198
- Ventricular remodeling in heart failure.J Card Fail. 2002; 8: S476-S485
- Cardiomyocyte apoptosis is associated with increased wall stress in chronic failing left ventricle.Eur Heart J. 2003; 24: 742-751
- Apoptosis in heart failure represents programmed cell survival, not death, of cardiomyocytes and likelihood of reverse remodeling.J Card Fail. 2002; 8: S512-S517
- New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress.Lancet. 1998; 352: SI34-SI38
- Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity.J Card Fail. 2004; 10: 334-338
- Increased urinary 15-F2t-isoprostane concentrations in patients with non-ischaemic congestive heart failure: a marker of oxidative stress.Heart. 2003; 89: 871-874
- Pathophysiology of congestive heart failure.Rev Cardiovasc Med. 2003; 4: S14-S20
Article info
Publication history
Accepted:
April 27,
2005
Received in revised form:
April 18,
2005
Received:
December 30,
2004
Hamamatsu, Japan; Nagoya, JapanIdentification
Copyright
© 2005 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
